Tanya Dorff, MD

Neeraj Agarwal, MD

GU Oncology Now

In the second part of this peer-to-peer discussion at the 2023 Uromigos Live &amp; Unplugged event, Tanya Dorff, MD, City of Hope, and Neeraj Agarwal, MD, University of Utah, summarize the toxicities associated with talazoparib for patients with metastatic castration-resistant prostate cancer.They also provide recommendations for monitoring adverse events in the first few months of treatment, as well as treatment dosage and duration considerations.View the other parts of this discussion, including <a href="https://guoncologynow.com/post/talazoparib-plus-enzalutamide-talapro-2-results-and-subset-analyses" target="_blank" rel="noopener">Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset Analyses</a>, <a href="https://guoncologynow.com/post/how-has-talapro-2-changed-the-standard-of-care-for-first-line-mcrpc-with-hrr-mutations" target="_blank" rel="noopener">How Has TALAPRO-2 Changed the Standard of Care for First-Line mCRPC With HRR Mutations</a>, and <a href="https://guoncologynow.com/post/importance-of-genomic-testing-for-patients-with-metastatic-prostate-cancer" target="_blank" rel="noopener">Importance of Genomic Testing for Patients With Metastatic Prostate Cancer</a>.

TALAPRO-2: Toxicities and Treatment Duration

Uromigos Live 2023

Drs. Dorff and Agarwal summarize the toxicities associated with talazoparib for patients with metastatic CRPC.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe